Vinva Investment Management Ltd Boosts AbbVie Stake by 24%

The institutional investor now owns over 162,000 shares of the pharmaceutical company.

Published on Mar. 8, 2026

Vinva Investment Management Ltd increased its stake in AbbVie Inc. (NYSE:ABBV) by 24% during the third quarter, according to a recent filing with the Securities and Exchange Commission. The institutional investor now owns 162,584 shares of the pharmaceutical company's stock, valued at $36.3 million.

Why it matters

AbbVie is one of the largest pharmaceutical companies in the world, known for blockbuster drugs like Humira. Institutional investors closely monitor the company's performance and outlook, as changes in their holdings can signal broader market trends and investor sentiment.

The details

Vinva Investment Management Ltd purchased an additional 31,451 shares of AbbVie during the third quarter, bringing its total position to 162,584 shares. This represents approximately 0.7% of Vinva's overall portfolio. AbbVie's stock has seen strong performance in recent quarters, driven by the continued success of its immunology and oncology drug franchises.

  • Vinva Investment Management Ltd increased its AbbVie stake during the third quarter of 2026.

The players

Vinva Investment Management Ltd

An institutional investment firm that manages a portfolio of stocks, including a position in pharmaceutical giant AbbVie.

AbbVie Inc.

A global biopharmaceutical company that focuses on discovering, developing, and commercializing therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Vinva Investment Management's increased stake in AbbVie reflects the continued investor confidence in the pharmaceutical company's ability to deliver strong financial performance and growth, driven by its diverse portfolio of innovative drugs.